Takashi Taniguchi Selected Research

UCP0054278

1/2011	Protection against dopaminergic neurodegeneration in Parkinson's disease-model animals by a modulator of the oxidized form of DJ-1, a wild-type of familial Parkinson's disease-linked PARK7.
3/2009	Protection against oxidative stress-induced neurodegeneration by a modulator for DJ-1, the wild-type of familial Parkinson's disease-linked PARK7.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takashi Taniguchi Research Topics

Disease

50	Systemic Scleroderma (Systemic Sclerosis) 01/2020 - 10/2011
17	Fibrosis (Cirrhosis) 02/2020 - 01/2012
15	Parkinson Disease (Parkinson's Disease) 01/2017 - 03/2002
12	Inflammation (Inflammations) 02/2020 - 02/2015
12	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2020 - 08/2012
11	Alzheimer Disease (Alzheimer's Disease) 01/2011 - 04/2002
9	Sclerosis 08/2017 - 01/2012
6	digital ulcers 01/2018 - 10/2011
5	Amyloid Plaque 01/2011 - 04/2002
4	Pulmonary Fibrosis (Fibrosing Alveolitis) 02/2018 - 04/2014
3	Pulmonary Arterial Hypertension 01/2020 - 08/2014
3	Telangiectasis (Telangiectasia) 02/2018 - 01/2016
3	Vascular System Injuries 01/2018 - 10/2011
3	Pathologic Processes 01/2017 - 05/2015
3	Systemic Lupus Erythematosus (Libman-Sacks Disease) 10/2014 - 01/2013
3	Diffuse Scleroderma (Progressive Systemic Sclerosis) 06/2014 - 10/2011
3	Brain Ischemia (Cerebral Ischemia) 11/2009 - 03/2008
3	Ischemia 03/2009 - 02/2003
3	Neuroblastoma 11/2006 - 11/2002
2	Cicatrix (Scar) 01/2018 - 06/2016
2	Leukemia 01/2017 - 12/2009
2	Disease Progression 01/2017 - 06/2011
2	Neoplasms (Cancer) 06/2015 - 05/2015
2	Pathologic Neovascularization 01/2015 - 05/2014
2	Rheumatoid Arthritis 05/2014 - 06/2011
2	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2009 - 06/2008
2	Infarction (Infarctions) 01/2009 - 03/2008
1	Atopic Dermatitis (Atopic Eczema) 06/2021
1	Blister (Bulla) 01/2019
1	Localized Scleroderma (Morphea) 11/2018
1	Contracture 02/2018
1	Dermatitis 01/2017
1	Pruritus (Itching) 01/2017

Drug/Important Bio-Agent (IBA)

10	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019 - 08/2012
9	Proteins (Proteins, Gene)FDA Link 01/2013 - 02/2003
8	Bleomycin (Blenoxane)FDA LinkGeneric 02/2020 - 01/2015
6	Transcription Factors (Transcription Factor)IBA 11/2018 - 04/2014
6	indium-bleomycinIBA 01/2018 - 04/2014
6	Amyloid beta-PeptidesIBA 02/2007 - 04/2002
5	RotenoneIBA 01/2011 - 11/2002
5	Neuroprotective AgentsIBA 11/2009 - 02/2003
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2018 - 10/2015
4	ChemokinesIBA 01/2018 - 06/2008
4	AdipokinesIBA 05/2015 - 07/2013
4	ImmunosorbentsIBA 01/2015 - 01/2013
4	EnzymesIBA 01/2015 - 01/2013
4	Dopamine (Intropin)FDA LinkGeneric 01/2011 - 03/2002
4	Peptides (Polypeptides)IBA 02/2007 - 04/2002
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 02/2018 - 06/2008
3	AdiponectinIBA 01/2018 - 03/2013
3	CytokinesIBA 01/2017 - 06/2008
3	Pharmaceutical PreparationsIBA 01/2017 - 04/2014
2	Immunoglobulin G (IgG)IBA 06/2021 - 01/2018
2	Hydroxyproline (4 Hydroxyproline)IBA 02/2020 - 01/2015
2	Biological ProductsIBA 01/2019 - 10/2015
2	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2018 - 06/2011
2	ProgranulinsIBA 11/2018 - 12/2015
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 11/2018 - 12/2015
2	Rituximab (Mabthera)FDA Link 06/2018 - 05/2014
2	Heparin (Liquaemin)FDA LinkGeneric 02/2018 - 06/2015
2	RNA Polymerase IIIIBA 07/2016 - 05/2015
2	AutoantibodiesIBA 05/2015 - 12/2014
2	anti-scl-70 autoantibodiesIBA 05/2015 - 05/2014
2	Nicotinamide PhosphoribosyltransferaseIBA 08/2014 - 07/2013
2	Bosentan (Tracleer)FDA Link 04/2014 - 10/2011
2	CathepsinsIBA 05/2013 - 01/2012
2	UCP0054278IBA 01/2011 - 03/2009
2	Amyloid (Amyloid Fibrils)IBA 01/2011 - 12/2010
2	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 02/2009 - 12/2008
2	triphenyltetrazoliumIBA 01/2009 - 03/2008
2	HMGB1 Protein (HMG1)IBA 12/2004 - 02/2003
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 02/2020
1	Complement Factor D (Factor D)IBA 01/2020
1	Chemical Warfare AgentsIBA 01/2019
1	Aquaporins (Water Channels)IBA 01/2019
1	SteroidsIBA 06/2018
1	Heparin-binding EGF-like Growth Factor (HB-EGF)IBA 02/2018
1	CarbohydratesIBA 02/2018
1	AntigensIBA 02/2018
1	Epidermal Growth Factor (EGF)IBA 02/2018
1	AdipoRonIBA 01/2018
1	Adiponectin ReceptorsIBA 01/2018
1	tocilizumab (atlizumab)FDA Link 08/2017
1	InterleukinsIBA 08/2017
1	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 08/2017
1	Interleukin-6 (Interleukin 6)IBA 08/2017
1	fluorodopa F 18IBA 01/2017
1	Thrombospondin 1IBA 01/2017
1	InterferonsIBA 01/2017
1	LigandsIBA 01/2017
1	Keratins (Keratin)IBA 01/2017
1	trioctyl phosphine oxide (TOPO)IBA 01/2017
1	Glycyrrhizic Acid (Glycyrrhizin)IBA 01/2017
1	FluorineIBA 01/2017
1	Type I DNA Topoisomerases (Topoisomerase I)IBA 01/2017
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2017
1	Nucleosomes (Nucleosome)IBA 10/2016
1	Protein Isoforms (Isoforms)IBA 08/2016

Therapy/Procedure

9	Therapeutics 01/2019 - 03/2002
2	Aftercare (After-Treatment) 06/2021 - 12/2009